A stepwise approach to implementing pharmacogenetic testing in the primary care setting

Author:

Weitzel Kristin Wiisanen1,Duong Benjamin Q2,Arwood Meghan J1,Owusu-Obeng Aniwaa3,Abul-Husn Noura S3,Bernhardt Barbara A4,Decker Brian5,Denny Joshua C6,Dietrich Eric1,Gums John1,Madden Ebony B7,Pollin Toni I8,Wu Rebekah Ryanne9,Haga Susanne B9ORCID,Horowitz Carol R10

Affiliation:

1. Department of Pharmacotherapy & Translational Research, University of Florida, Gainesville, FL 32608, USA

2. Department of Pharmacy, Nemours/Alfred I DuPont Hospital for Children, Wilmington, DE 19803, USA

3. The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

4. Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA

5. Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202, USA

6. Department of Medicine & Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

7. National Human Genome Research Institute, Division of Genomic Medicine, Bethesda, MD 20892, USA

8. Department of Medicine & Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA

9. Center for Applied Genomics & Precision Medicine, Duke University School of Medicine, Durham, NC 27708, USA

10. Department of Health Policy & Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Abstract

Pharmacogenetic testing can help identify primary care patients at increased risk for medication toxicity, poor response or treatment failure and inform drug therapy. While testing availability is increasing, providers are unprepared to routinely use pharmacogenetic testing for clinical decision-making. Practice-based resources are needed to overcome implementation barriers for pharmacogenetic testing in primary care.The NHGRI’s IGNITE I Network (Implementing GeNomics In pracTicE; www.ignite-genomics.org ) explored practice models, challenges and implementation barriers for clinical pharmacogenomics. Based on these experiences, we present a stepwise approach pharmacogenetic testing in primary care: patient identification; pharmacogenetic test ordering; interpretation and application of test results, and patient education. We present clinical factors to consider, test-ordering processes and resources, and provide guidance to apply test results and counsel patients. Practice-based resources such as this stepwise approach to clinical decision-making are important resources to equip primary care providers to use pharmacogenetic testing.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Reference65 articles.

1. Pharmacogenomics in the clinic

2. Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects

3. Administration FaD. Table of pharmacogenomic biomarkers in drug labeling (2019). www.fda.gov/Drugs/ScienceResearch/ucm572698.htm

4. Pharmacogenomics

5. Global direct-to-consumer genetic testing market to reach $6.36 billion by 2028. PRNewswire (2019). www.prnewswire.com/news-releases/global-direct-to-consumer-genetic-testing-market-to-reach-6-36-billion-by-2028-300853946.html

Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3